A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.
New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
At the American Association of Clinical Endocrinology 2025 Annual Meeting, Jaime Almandoz, MD, MBA, FTOS, discussed the importance of continuing medical treatment for patients with obesity following...
Researchers set out to determine the prevalence of pickleball-related fractures examined in United States emergency departments from 2002 to 2022, as well the demographics associated with those fractures....
The US Preventive Services Task Force assessed the benefits and harms of osteoporosis screening in adults aged 40 years or older without a known diagnosis of osteoporosis or history of fragility fractures.
...
In this COVID-19 roundup, researchers report on the risk of health issues and death among patients hospitalized with COVID-19 at 3 year-follow-up, the widespread overuse of antibiotics among patients with...
A randomized clinical trial found that a nurse-led intervention strategy could improve systolic blood pressure and non-high-density lipoprotein cholesterol in patients with HIV, reducing their risk of...
